ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma |
| |
Authors: | Teraishi Fuminori Kagawa Shunsuke Watanabe Takanori Tango Yasuhisa Kawashima Takeshi Umeoka Tatsuo Nisizaki Masahiko Tanaka Noriaki Fujiwara Toshiyoshi |
| |
Institution: | Division of Surgical Oncology, Department of Surgery, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan. |
| |
Abstract: | The EGF (epidermal growth factor) receptor-tyrosine kinase inhibitor ZD1839 (Gefitinib, 'Iressa') blocks the cell signaling pathways involved in cell proliferation, survival, and angiogenesis in various cancer cells. TNF-related death apoptosis inducing ligand (TRAIL) acts as an anticancer agent. We investigated the antitumor effects of ZD1839 alone or in combination with TRAIL against human esophageal squamous cell cancer (ESCC) lines. Although all ESCC cells expressed EGF receptor at a protein level, the effect of ZD1839 on cell growth did not correlate with the level of EGFR expression and phosphorylation of EGF receptor protein in ESCC lines. ZD1839 caused a dose-dependent growth arrest at G0-G1 phase associated with increased p27 expression. As TE8 cells are resistant to TRAIL, we tested whether ZD1839 combined with TRAIL induced apoptosis of TE8 cells via the inhibition of EGF receptor signaling by ZD1839. ZD1839 inhibited the phosphorylation of Akt, and enhanced TRAIL-induced apoptosis via activation of caspase-3 and caspase-9, and inactivation of Bcl-xL. Our results indicated that ZD1839 has anti-cancer properties against human esophageal cancer cells. ZD1839 also augmented the anti-cancer activity of TRAIL, even in TRAIL-resistant tumors. These results suggest that treatment with ZD1839 and TRAIL may have potential in the treatment of ESCC patients. |
| |
Keywords: | EGF epidermal growth factor EGFR epidermal growth factor receptor ESCC esophageal squamous cell carcinoma FACS fluorescence-activated cell-sorting MTT 3-(4 5-dimethylthiazol-2-yl)-2 5-diphenyltetrazolium bromide NSCLCs non-small cell lung cancers PI propidium iodide PI3K phosphatidylinositol 3-kinase TKI tyrosine kinase inhibitor TRAIL tumor necrosis factor-related apoptosis inducing ligand |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|